SCHEMBL20147513

SCHEMBL20147513

CC(C)N1CCC(CN(C)C)(NC(=O)OCC2CC2)CC1

nearest known ligand 0.42

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
RET P07949 4/20 0.42
BCHE P06276 2/20 0.32
MAOB P27338 1/20 0.32
HRH3 Q9Y5N1 9/20 0.32
ACHE P22303 2/20 0.32
CHRM3 P20309 1/20 0.31
KCNH2 Q12809 3/20 0.31
CTSL P07711 1/20 0.31
CTSS P25774 1/20 0.31
CYP2D6 P10635 1/20 0.30
CTSK P43235 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20069722 0.86 RET (0.43) RETBCHECHRM3
SCHEMBL20147514 0.83 RET (0.42) RETHRH3
SCHEMBL20147496 0.82 RET (0.40) RETHRH3KCNH2CYP2D6
SCHEMBL20147481 0.82 RET (0.36) RETBCHEMAOBACHECHRM3
SCHEMBL20069514 0.82 RET (0.38) RETBCHEMAOBHRH3ACHE
SCHEMBL20147517 0.81 RET (0.41) RETHRH3KCNH2CYP2D6
SCHEMBL20147516 0.76 MMP1 (0.31)
SCHEMBL20147486 0.75 RET (0.41) RETHRH3
SCHEMBL20147510 0.75 RET (0.40) RETHRH3
SCHEMBL20147680 0.75 RET (0.40) RETHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RET 1/4885BCHE 4084/4885MAOB 3003/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 RET 1/4885BCHE 4084/4885MAOB 3003/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RET 1/4885BCHE 4084/4885MAOB 3003/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RET 1/4885BCHE 4084/4885MAOB 3003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.